Amundi Sells 1,359 Shares of Phreesia, Inc. (NYSE:PHR)

Amundi trimmed its holdings in Phreesia, Inc. (NYSE:PHR) by 37.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,248 shares of the company’s stock after selling 1,359 shares during the period. Amundi’s holdings in Phreesia were worth $57,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in shares of Phreesia during the third quarter valued at about $316,000. Charles Schwab Investment Management Inc. lifted its position in shares of Phreesia by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,239 shares of the company’s stock valued at $10,193,000 after purchasing an additional 16,112 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Phreesia during the third quarter valued at about $549,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PHR. Truist Financial raised their price target on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a report on Thursday, March 13th. KeyCorp raised their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Finally, Robert W. Baird decreased their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $31.33.

Insider Transactions at Phreesia

In other news, COO Evan Roberts sold 3,519 shares of Phreesia stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total value of $105,781.14. Following the completion of the transaction, the chief operating officer now owns 741,197 shares in the company, valued at $22,280,381.82. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Amy Beth Vanduyn sold 1,311 shares of Phreesia stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $34,885.71. Following the completion of the transaction, the senior vice president now owns 115,633 shares of the company’s stock, valued at $3,076,994.13. The trade was a 1.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 162,442 shares of company stock worth $4,611,300 over the last quarter. Corporate insiders own 5.80% of the company’s stock.

Phreesia Price Performance

PHR opened at $27.45 on Friday. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -18.68 and a beta of 1.03. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $27.33 and a 200-day moving average price of $24.08. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.